Silver Bullet Enterprises
3620 W. 10th St., #180
Greeley, CO 80634
970-545-2360 e-mail:
sales@silverbulletenterprises.comhome: www.silverbulletenterprises.com
We are retailers of Colloidal Silver Generation Equipment. We believe that the information we provide and the equipment we sell can help you to improve the quality of life for yourself and your family . That is our goal.
The Conventional Medical Arsenal for Treating Influenza
Conventional medical authorities battle potential "flu" epidemics using vaccination as their primary weapon. This method of Flu treatment is approved by the FDA.
The vaccination "weapon", is at best, a double edged sword.
The apparent benefit is a reduced risk of catching Influenza.
This benefit may be defeated if the strain against which the vaccine is effective is not the predominant strain affecting the general population in any given flu season. ( If you were vaccinated against type A but type B is the one you are exposed to, you may get the flu anyway. This is a "not uncommon" occurrence.)
The "downside" of flu vaccination, for many people appears to outweigh the potential benefit.
Link to a list of "Peer Reviewed Citations of flu vaccine damage"
To say the least, the injection of a complex biological compound, containing Thimerosal…a form of Mercury…as a preservative may not be in the best interest of the patient. (The Thimerosol Controversy)
Quoting information from: autism-mercury.com
"In June 1999, the Food and Drug Administration discovered that "Infants who receive thimerosal containing vaccine at several visits may be exposed to more mercury than recommended by Federal guidelines for total mercury exposure." Thimerosal, a preservative used in some vaccines to prevent contamination, is 49.6% mercury by weight. Infants who are being vaccinated using multi-dose vials with thimerosal can receive 62.5 micrograms of mercury per visit.
For an average sized child this represents an exposure approximately 100 times the 0.1 micrograms per kilogram of daily exposure considered safe by the Environmental Protection Agency. The manufactures safety data sheet for thimerosal states, "Highly toxic…Danger of cumulative effects…Avoid prolonged or repeated exposure… and the Chemical, physical, and toxicological properties have not been thoroughly investigated.""In general the risks inherent with Flu vaccination include:
Soreness at the injection site
Muscle aches & pains
Fever
Flu
Increased risk of /exacerbation of problems caused by Mercury exposure / toxcicity (Iowa, among other states, has banned the injection of infants & pregnant women with compounds containing more than trace amounts of mercury...specifically to prevent such complications.)
Alzheimer’s Disesase ... Increased Risk
Hugh Fudenberg, MD, an immunogeneticist and biologist, Founder and
Director of Research, Neurolmmuno Therapeutic Research Foundation, with
numerous papers published in peer review journals, has reported that if an
individual had five consecutive flu shots between 1970 and 1980 (the
years studied), his/her chances of getting Alzheimer's Disease is ten
times higher than if they had zero, one, or two shots. Information
comes from Dr. Fudenberg's speech at the NVIC International Vaccine
Conference, Arlington, VA September, 1997.
Dr. Boyd Haley, Professor and Chair of the Department of Chemistry at the
University of Kentucky, Lexington has done extensive research in the area of
mercury toxicity and the brain. His research has established a likely connection
between mercury toxicity and Alzheimer’s disease. (The Relationship of
Toxic Effects of Mercury to Exacerbation of the Medical Condition Classified as
Alzheimer’s Disease by Boyd E. Haley, PhD.)
In a paper published in collaboration with researchers at University of
Calgary, Haley stated that “seven of the characteristic markers that we look
for to distinguish Alzheimer's disease can be produced in normal brain tissues,
or cultures of neurons, by the addition of extremely low levels of mercury.”
(NeuroReport, 12(4):733-737, 2001)
Does the above information establish, beyond a doubt, a "cause and effect"
relationship between mercury toxicity and alzheimer's? No,
certainly not.
It does establish a reasonable basis for the average person to exhibit extreme caution in the decision making process related to any mercury containing product that might be ingested or injected.
Autism in children. (Autism defined) (Autism RNA Therapy)
Every year in the United States flu vaccine is in some degree of short supply, with a "dosage shortfall" projected by both news agencies and medical authorities. Blame is spread around to just about every available culprit. One year the problem was even attributed to action or inaction by the President of the United States. (Blaming the President for this one, in my opinion is just dumb.)
Commercial anti-virals are also available, by prescription.
As a general rule, these drugs are not readily available, expensive, and some debate their efficacy. They have received FDA approvals.
Studies have shown that all four drugs can reduce the duration of flu symptoms by 1 day if taken within 2 days of the onset of the illness. There is no information about how effective these drugs are if treatment is started more than 2 days after onset of flu symptoms.
The four available medicines include: (as listed by www.mydna.com)
"Tamiflu (oseltamivir)
helps adults 18 years and older and Relenza (zanamivir) helps adults and children 7 years and older who have an uncomplicated flu infection and who have had symptoms for no more than two days. FDA also has approved Tamiflu for use in children 1 year of age and older who have had symptoms for no more than 2 days. Both treat influenza type A and type B infections.Flumadine (rimantadine)
helps adults who have influenza type A virus infections. It has no effect on influenza type B virus infections.Symmetrel (amantadine)
may be taken by adults and children who are 1 year of age and older to prevent and treat type A influenza virus infections. Amantadine, however, is more likely to cause side effects such as lightheadedness and inability to sleep more often than is rimantadine.Relenza (Zanamivir) Adults and pediatric patients at least 7 years of age who have influenza symptoms that appeared within the previous day or two. Typical symptoms of influenza include sudden onset of fever, cough, headache, muscular weakness, and sore throat.
To work well, you must take these medicines within 48 hours after the flu begins. "
Prevention & Treatments that Work (next) General Information & Symptoms Influenza & You( back)
We are not licensed Medical Professionals. We endeavor to provide accurate and useful information BUT we do not guarantee the accuracy of information on this site or any site to which we have linked. We specifically deny all liability for the use of any information on this site. We strongly recommend consultation with licensed professionals prior to beginning, ending or changing the course of treatment for any medical condition.
Citations of flu vaccine damage
Breman JG, et al. Guillain-Barre syndrome and its relationship to swine influenza vaccination in Michigan, 1976-1977. Am J Epidemiol. 1984 Jun;119(6):880-9. PMID: 6731430; UI: 84228448.
Ehrengut W. [Side effects of influenza vaccinations]. Dtsch Med Wochenschr. 1979 Dec 28;104(52):1836. German. No abstract available.PMID: 520180; UI: 80091277.
Ehrengut W, et al. [Neurological complications after influenza vaccination]. MMW Munch Med Wochenschr. 1977 May 20;119(20):705-10. German. PMID: 406554; UI: 77212853.
Gerth HJ. [Polymyalgia rheumatica and influenza vaccination]Dtsch Med Wochenschr. 1992 Aug 14;117(33):1259-60. German. No abstract available.PMID: 1499526 [PubMed - indexed for MEDLINE]
Hasselbacher P. Neuropathy after influenza vaccination [letter]. Lancet. 1977 Mar 5;1(8010):551-2. No abstract available.PMID: 65654; UI: 77122811.
Honkanen PO, et al. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med. 1996 Jan 22;156(2):205-8. PMID: 8546555; UI: 96136003.
Keenlyside RA, et al. Fatal Guillain-Barre syndrome after the national
influenza immunization program. Neurology. 1980 Sep;30(9):929-33. PMID: 6252515;
UI: 81031247.
Fifty-eight fatal cases of Guillain-Barre syndrome (GBS) were reported during
the 1976 to 1977 National Influenza Program: Thirty-two (58%) of these patients
had received the A/New Jersey influenza vaccine. The mean interval from
vaccination to onset was 3.9 weeks, and the incidence of preceding illness in
vaccinated or unvaccinated patients was similar. Fifty-eight percent had at
least one chronic disease before onset. The clinical features were similar in
vaccinated and unvaccinated patients. Most deaths followed medical complications
of respiratory paralysis: Fifteen had pneumonia, 29 (83%) died suddenly, 15 had
sudden arrhythmias or hypotension, and 7 had myocardial infarction or pulmonary
embolus.
Liozon E, Ittig R, Vogt N, Michel JP, Gold G. Polymyalgia rheumatica following influenza vaccination.J Am Geriatr Soc. 2000 Nov;48(11):1533-4. No abstract available.PMID: 11083341 [PubMed - indexed for MEDLINE]
Lear JT, et al. Bullous pemphigoid following influenza vaccination. Clin Exp Dermatol. 1996 Sep;21(5):392. No abstract available.PMID: 9136169; UI: 97281896.
Lasky T, et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998 Dec 17;339(25):1797-802. PMID: 9854114; UI: 99061022.
A patient is reported in whom bilateral optic neuritis developed following an influenza vaccination. From complete blindness (absence of light perception) in one eye, the patient's vision returned to normal following steroid treatment.
Perez C, Maravi E. Polymyalgia rheumatica following influenza vaccination.Muscle Nerve. 2000 May;23(5):824-5. No abstract available.PMID: 10797410 [PubMed - indexed for MEDLINE]
Poser C . Neurological complications of swine influenza vaccination.
Acta Neurol Scand 1982 Oct;66(4):413-31
The emphasis upon the remarkably large number of cases of Guillain-Barre
syndrome which resulted from the 1976 National Swine Influenza immunization
program in the U.S.A. has obscured the fact that other neurological
complications, involving the central nervous system also occurred. The
anatomical distribution of lesions is almost identical with that seen following
other types of vaccination: involvement of the brain, cerebellum, optic nerve,
cranial nerves and spinal cord occurred with approximately the same frequency. 5
instances of the very rare subacute or chronic, progressive, post-vaccinal
encephalopathy are described, a situation which is identical to the subacute and
chronic forms of polyradiculoneuropathy. In a number of cases, in particular the
myelopathies, a subclinical involvement of peripheral nerves was demonstrated by
means of electrodiagnostic studies, illustrating the often overlooked fact that
central nervous system involvement will mask peripheral nerve lesions. The
etiological significance of the swine influenza vaccination was overlooked and
completely erroneous diagnoses were established in a surprisingly large number
of the 26 new cases reported here. PMID: 6128862, UI: 83070654
Langmuir AD, et al. An epidemiologic and clinical evaluation of
Guillain-Barre syndrome reported in association with the administration of swine
influenza vaccines. Am J Epidemiol. 1984 Jun;119(6):841-79. PMID: 6328974; UI:
84228447.
As a result of a court order, computerized summaries of approximately 1,300
cases reported as Guillain-Barre syndrome by state health departments to the
Centers for Disease Control during the intensive national surveillance
instituted following the swine influenza vaccination program in 1976-1977 became
available for further study. Although the data were not uniformly adequate to
confirm the diagnosis of Guillain-Barre syndrome, they were sufficient to enable
classification according to extent of motor involvement. Vaccinated cases with
"extensive" paresis or paralysis occurred in a characteristic epidemiologic
pattern closely approximated by a lognormal curve, suggesting a causal
relationship between the disease and the vaccine. Cases with "limited" motor
involvement showed no such pattern, suggesting that this group included a
substantial proportion of cases which were unrelated to the vaccine. The effect
attributed to the vaccine lasted for at least six weeks and possibly for eight
weeks but not longer. The relative risk of acquiring "extensive" disease over a
six-week period following vaccination ranged from 3.96 to 7.75 depending on the
particular baseline estimate of expected normal or endemic incidence that was
chosen. Correspondingly, the number of cases that could be attributed to the
vaccine over the six-week period ranged from 211 to 246, or very slightly higher
over an eight-week period if the lowest baseline estimate was used. The total
rate of Guillain-Barre syndrome cases attributed to prior use of the vaccine was
4.9 to 5.9 per million vaccinees.
Mader R, et al. Systemic vasculitis following influenza
vaccination--report of 3 cases and literature review. J Rheumatol. 1993
Aug;20(8):1429-31. Review. PMID: 8230034; UI: 94046875.
Influenza vaccination is a widely accepted practice particularly among the
elderly and high risk individuals. Minor and transitory
side effects following the vaccination are common while systemic complications
are infrequently reported. We describe 3 patients who developed systemic
vasculitis following influenza vaccination. With increasing use of influenza
vaccination, attention should be drawn to the possible expression of systemic
adverse effects such as vasculitis.
[Vaccination and the Guillan-Barre syndrome]. Ned Tijdschr Geneeskd. 1978 Nov 11;122(45):1780. Dutch. No abstract available.PMID: 703884; UI: 79032243.
Nicholson, Karl G.; Nguyen-Van-Tam, Jonathan S.; Ahmed, Ala'eldin H.; et al. "Randomized Placebo-Controlled Crossover Trial on Effect of Inactivated Influenza Vaccine on Pulmonary Function in Asthma" Lancet (01/31/98) Vol. 351, No. 9099, P. 326;
British researchers report that there is a correlation between pulmonary-function abnormalities and complications due to flu vaccination, although the risk is quite small and the benefits of vaccination outweigh the complications that may occur. The team studied 262 adults in a double-blind, placebo-controlled crossover study of 262 adults to evaluate the safety of flu vaccination in asthma patients. Despite current guidelines, asthma patients often do not receive annual flu shots, in part, due to concerns that the vaccine will trigger exacerbations. For two weeks before the first injection until two weeks after the second injection, the subjects kept a record of daily peak expiratory flow (PEF), respiratory symptoms, medication, medical consultations, and hospital admissions. Of the 255 patients with paired data, 11 saw a reduction in PEF greater than 20 percent, while eight had a decline in PEF of more 30 percent. Only three of the placebo receiving subjects had PEF reduction greater than 20 percent, and none had a reduction greater than 30 percent. When the researchers excluded subjects with colds--which can trigger exacerbations and may be mistaken for vaccine-related adverse events--there was no significant difference in PEF decline, although they said the difference for PEF declines of more than 30 percent approached significance.
Retailliau HF, et al. Illness after influenza vaccination reported through a nationwide surveillance system, 1976-1977. Am J Epidemiol. 1980 Mar;111(3):270-8. PMID: 7361749; UI: 80150827.
Saito H, et al. Acute cerebellar ataxia after influenza vaccination with recurrence and marked cerebellar atrophy. Tohoku J Exp Med. 1989 May;158(1):95-103. PMID: 2781544; UI: 89388779.
Schmutz JL, et al. [Does influenza vaccination induce bullous
pemphigoid]? Ann Dermatol Venereol. 1999 Oct;126(10):765. French. No abstract
available.PMID: 10604026; UI: 20071693.
Schonberger LB, et al. Guillain-Barre syndrome: its epidemiology and associations with influenza vaccination. Ann Neurol. 1981;9 Suppl:31-8. PMID: 7224614; UI: 81182844.
Schonberger LB, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol. 1979 Aug;110(2):105-23. PMID: 463869; UI: 79228981.
USP II Generator (our best) USP Generator Other Products Conventional Generators Order Form Literature Merchandise Disclaimer Home